Big Pharma Likes Big Trials, Biotech CEO Says; Tufts Defends R&D Estimate

Large pharmaceutical companies are comfortable with high R&D costs because they create a barrier to entry in the industry, Cancer Therapeutics, Inc. CEO Robert Oldham, MD, maintained during a Capitol Hill briefing sponsored by the Manhattan Institute June 3